Webinars
Sign up for one of our free Webinars to learn about basic and advanced science topics, get tips and techniques for your lab, or find out more about new technologies and products. Webinars cover educational topics in life science research, drug discovery, clinical research, applied sciences, clinical and molecular diagnostics, and more. Live presentations include the opportunity to ask questions via chat. Don't worry if you missed a presentation date—past Webinars are available for on-demand viewing.
Upcoming Webinars
Mastering Quality Management Systems: Ensuring Compliance with the New FDA LDT Rule
In the evolving regulatory landscape for diagnostics, the FDA LDT rule emphasizes the necessity for robust quality management systems (QMS). Join Promega and McDermott for an informative webinar that explores the significance of these systems in developing IVD assays. McDermott will provide an overview of the FDA rule, its phases, and the critical role of a QMS in compliance. Promega will demonstrate how laboratory quality systems can leverage its ISO-certified quality framework to streamline FDA submissions. This webinar will equip you with considerations for building an effective QMS, facilitating regulatory compliance and enhancing the reliability of your IVD assays.
Presenters:
Michael W. Ryan, Partner, McDermott Will & Emery
Abigail Davis, Director, Quality Assurance, Promega
Date:
Wednesday, August 28, 2024
Register Here:
1pm CDT / 2pm EDT / 11am PDTDefining CAR T Cell Potency: Advances in Functional Analysis
Chimeric antigen receptor (CAR) modified T cells represent a promising avenue in immunotherapy, offering potential cures for many diseases. To ensure therapeutic efficacy and safety, the development and manufacturing of CAR T cells requires in vitro potency assays. The challenge lies in accurately measuring the potency of CAR T cells to predict in vivo performance, which is critical for regulatory approval and clinical success. In this webinar, we will explore cutting-edge potency analysis tools for CAR T development and testing pipelines. Join us to learn how advanced techniques and integrated approaches can help your team ensure the development of potent and effective CAR T cell therapies.
Presenters:
Dr. Nicholas Hess, Associate Product Manager, Promega Corporation
Dr. Danielle Califano, Product Manager, Impedance Assay Systems, Axion BioSystems
Date:
Wednesday, September 4, 2024 - 9am CDT / 10am EDT / 3pm London / 4pm Amsterdam-Paris
Thursday, September 5, 2024 - 12pm Singapore / 2pm Sydney / 1pm Seoul / 9:30am New Delhi
Register Here:
Wednesday, Sept 4 Thursday, Sept 5Illuminating New Frontiers-Cracking the Undruggable Code
We invite you on a groundbreaking journey across the evolving landscape of drug discovery. This three-day virtual event unites trailblazers in science and industry to explore how innovative approaches are reshaping our ability to tackle 'undruggable' targets. From the complexities of the RAS pathway and the intricacies of protein-protein interactions to the pioneering fields of targeted protein degradation/induced proximity and RNA targeting, each day illuminates a different frontier of therapeutic potential.
We stand at the cusp of a new era, where challenges become opportunities for breakthroughs that extend beyond conventional boundaries. This event is a testament to the power of collaboration and innovation in unveiling new therapeutic strategies, offering hope for untreatable conditions. Join us as we navigate the cutting-edge of science, inspiring a future where every target is within our reach, and no patient is left without options.
Day 1 - Rethinking Undruggable Targets: New Insights into RAS and Protein Interactions
In the realm of drug discovery, certain targets have long been deemed "undruggable" due to their complex nature and the technical challenges associated with modulating them therapeutically. Among these, the RAS pathway stands out as an important element in cell signaling implicated in numerous cancers and diseases. Historically deemed undruggable due to its complex biochemistry and lack of suitable binding sites, RAS has recently witnessed a paradigm shift. Recent innovations in molecular biology—coupled with breakthroughs in drug design and technology—have challenged the notion that the RAS pathway is undruggable, leading to the development and market approval of RAS-targeting therapeutics. Similarly, protein-protein interactions (PPIs)—key elements of RAS signaling—represent untapped therapeutic potential, offering avenues to intervene in disease processes in ways previously deemed infeasible. In this session, we will explore the latest research targeting the RAS/MEK/ERK signaling pathway and learn about novel approaches being developed to manipulate and measure PPIs within RAS and other signaling networks.
Presenters:
Arvin Dar, PhD, Sloan Kettering Institute, MSKCC
HyunHee Cho, Novartis BioMedical Research
Tommy Turbyville, Ph.D, National Cancer Institute-RAS Initiative
Marie Schwinn, PhD, Promega
Date:
Tuesday, October 22 - 10am CDT / 11am EDT / 4pm London / 5pm Amsterdam-Paris
Day 2 - Next-Generation Therapeutics: The Power of Induced Proximity and Targeted Protein Degradation
Efforts to develop treatments for previously “undruggable” targets have launched a new phase in drug discovery, highlighted by the rise of next-generation therapeutics. Induced proximity, a strategy manipulating molecular interactions for desired outcomes, and targeted protein degradation, leveraging the cell's machinery to degrade pathogenic proteins, are forging new treatment paradigms and redefining our ability to modulate previously intractable molecular targets. In this session we will hear from leading experts as they present the latest research in this fast-moving field and learn how these cutting-edge strategies are transforming how we are tackling diseases once considered beyond reach.
Presenters:
Fleur Ferguson, PhD, University of California, San Diego
Georg Winter, PhD, Center for Molecular Medicine of the Austrian Academy of Sciences
Kristin M. Riching, PhD, Promega
Zoran Rankovic, PhD, The Institute of Cancer Research
Date:
Wednesday, October 23 - 10am CDT / 11am EDT / 4pm London / 5pm Amsterdam-Paris
Day 3 - Unlocking the Potential of RNA: New Paths for Targeting RNA
This session delves into the innovative realm of RNA as a key therapeutic target in modern drug discovery. Long considered a challenging prospect due to its dynamic nature and critical role in gene regulation, RNA offers unique opportunities for intervention. We will explore cutting-edge advancements in directly targeting RNA molecules and RNA-protein interactions, which are opening new avenues in treatment strategies. Discover how novel RNA-targeting techniques are transforming our ability to influence genetic and cellular functions, presenting potential cures for previously untreatable conditions.
Presenters:
Amanda Garner, PhD, University of Michigan
Matt Disney, PhD, Scripps Institute
John S. Schneekloth, Jr. (Jay), PhD, National Cancer Institute, Frederick, MD
Brad Swanson, Ph.D, Promega Corporation
Date:
Thursday, October 24 - 10am CDT / 11am EDT / 4pm London / 5pm Amsterdam-Paris
Register Here:
Full 3-day Event Day 1 only Day 2 only Day 3 only
